Journal
BRITISH JOURNAL OF CANCER
Volume 95, Issue 2, Pages 131-138Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6603233
Keywords
colorectal cancer; first-line; 5-fluorouracil; irinotecan; oxaliplatin; targeted agents
Categories
Ask authors/readers for more resources
Colorectal cancer ( CRC) caused over 500 000 deaths worldwide in 2002. Recent advances in the treatment of advanced disease include the incorporation of two new cytotoxic agents, irinotecan and oxaliplatin, into first- line regimens. The concept of planned sequential therapy involving three active agents during the course of a patient's treatment is evolving. Coupled with the integrated use of targeted monoclonal antibodies, we can now expect overall survival rates for advanced disease to exceed 20 months. This review considers current treatments and suggests where future progress may occur.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available